p3

Cambridge Healthtech Institute’s 6th Annual

Engineering Next-Generation Cancer Immunotherapies

January 20-21, 2020

Part of the Antibody Therapeutics pipeline

 

Based on the clinical successes of checkpoint inhibitors, the industry is now directing its attention to combination treatments, single agent therapeutics with multiple modes of action, confronting resistance mechanisms, reducing toxicity and the persistent challenge of solid tumors. Cambridge Healthtech Institute’s 6th Annual Engineering Next-Generation Cancer Immunotherapies conference provides a forum in which research scientists can discuss the contributions of protein engineering to the discovery and development of novel biotherapeutics in the IO space.

Coverage will include, but is not limited to:

  • Biparatopic bispecifics and conjugates
  • Discovery of additive target combinations and synergistic biology
  • Engineering challenges for novel CAR T configurations and combinations
  • Engineering considerations for new IO modalities (NK cells, macrophage therapies, single-domain antibodies, myeloid growth factor inhibitors, engineered cytokines)
  • Engineering therapeutic proteins for regional delivery
  • Lessons learned from early-stage combination trials; what strategies are emerging, and what does this mean for the future course of IO drug development?
  • Network and big data analysis in IO target discovery and development
  • Phenotypic reprogramming of T cells
  • Research models for immuno-oncology
  • Targeting the tumor microenvironment with therapeutic proteins
  • Understanding the biology of IO targets, pathways and combinations
  • Using scRNA-seq to evaluate tumor heterogeneity

 

* The program is subject to change without notice, due to unforeseen reason.







2020 Conferences & Training Seminars